Breast Imaging for Screening and Diagnosing Cancer

Policy Number: 2020T0375Z
Effective Date: October 1, 2020

Table of Contents Page
Coverage Rationale ................................................................. 1
Documentation Requirements .............................................. 2
Definitions ........................................................................... 2
Applicable Codes .................................................................. 3
Description of Services ....................................................... 4
Clinical Evidence ................................................................. 5
U.S. Food and Drug Administration .................................... 10
Centers for Medicare and Medicaid Services .................... 11
References ........................................................................... 12
Policy History/Revision Information .................................... 13
Instructions for Use ............................................................. 14

Coverage Rationale

Note: This policy does not address preventive benefit for breast cancer screening (including mammography); refer to the Coverage Determination Guideline titled Preventive Care Services for more information.

The following are proven and medically necessary for the following individuals:

- Digital mammography for individuals with dense breast tissue
- Diagnostic breast ultrasound
- Breast magnetic resonance imaging (MRI) for individuals who are high risk for breast cancer as defined as having any of the following:
  - History of radiation to the chest between ages 10 and 30
  - Lifetime risk estimated at greater than or equal to 20% based on models that are largely defined by family history (e.g., Gail, Claus, Tyrer-Cuzick or BRCAPRO)
  - Personal history of breast cancer (not treated with bilateral mastectomy)
  - Personal history with any of the following:
    - Li-Fraumeni Syndrome (TP53 mutation); or
    - Confirmed BRCA 1 or BRCA 2 gene mutations; or
    - Peutz-Jehgers Syndrome (STK11, LKB1 gene variations); or
    - PTEN gene mutation
  - Family history with any of the following:
    - At least one first-degree relative who has a BRCA1 or BRCA2 mutation; or
    - First-degree relative who carries a genetic mutation in the TP53 or PTEN genes (Li-Fraumeni syndrome and Cowden and Bannayan-Riley-Ruvalcaba syndromes, or Peutz-Jehgers Syndrome); or
    - At least two first-degree relatives with breast or ovarian cancer; or
    - One first-degree relative with bilateral breast cancer, or both breast and ovarian cancer; or
    - First or second-degree male relative (father, brother, uncle, grandfather) diagnosed with breast cancer
The following are unproven and not medically necessary due to insufficient evidence of efficacy:

- Automated breast ultrasound system
- Breast magnetic resonance imaging (MRI) for individuals with dense breast tissue not accompanied by defined risk factors as described above
- Computer-aided detection (CAD)
- Computer-aided tactile breast imaging
- Electrical impedance scanning (EIS)
- Magnetic resonance elastography (MRE)
- Molecular breast imaging (e.g., Scintimammography, positron emission mammography)

Note: For additional indications for breast MRI, refer to the Cardiology and Radiology Imaging Guidelines – Breast Imaging Guidelines.

### Documentation Requirements

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The documentation requirements outlined below are used to assess whether the member meets the clinical criteria for coverage but do not guarantee coverage of the service requested.

<table>
<thead>
<tr>
<th>CPT Codes*</th>
<th>Required Clinical Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>76376, 76377, 76498, 77046, 77047, 77048, 77049</td>
<td>Provider should call the number on the member’s ID card when referring for radiology services</td>
</tr>
<tr>
<td></td>
<td>Medical notes documenting all of the following:</td>
</tr>
<tr>
<td></td>
<td>o Recent history and physical</td>
</tr>
<tr>
<td></td>
<td>o Documentation to support medical necessity (i.e., family history, prior treatment, genetic testing results, other imaging studies and diagnostic results, etc.)</td>
</tr>
<tr>
<td></td>
<td>o Applicable CPT code</td>
</tr>
</tbody>
</table>

*For code descriptions, see the Applicable Codes section.

### Definitions

**Automated Breast Ultrasound**: Automated Breast Ultrasound is the first and only ultrasound system developed and US Food and Drug Administration (FDA) approved specifically for breast cancer screening in women with dense breast tissue who have not had previous breast biopsies or surgeries. It is used as an adjunct to mammography. The high center-frequency significantly sharpens detail resolution while the ultra-broadband performance simultaneously delivers distinct contrast differentiation. (ACS, 2016)

**Breast Specific Gamma Imaging (BSGI)**: BSGI, also known as scintimammography (SMM) or molecular breast imaging (MBI) is a noninvasive diagnostic technology that detects tissues within the breast that accumulate higher levels of a radioactive tracer that emit gamma radiation. The test is performed with a gamma camera after intravenous administration of radioactive tracers. Scintimammography has been proposed primarily as an adjunct to mammography and physical examination to improve selection for biopsy in patients who have palpable masses or suspicious mammograms. (ACS, 2016)

**Breast Ultrasound**: Ultrasound, also known as sonography, is an imaging method using sound waves rather than ionizing radiation to a part of the body. For this test, a small, microphone-like instrument called a transducer is placed on the skin (which is often first lubricated with ultrasound gel). It emits sound waves and picks up the echoes as they bounce off body tissues. The echoes are converted by a computer into a black and white image on a computer screen. Ultrasound is useful for evaluating some breast masses and is the only way to tell if a suspicious area is a cyst (fluid-filled sac) without placing a needle into it to aspirate (draw out) fluid. Cysts cannot accurately be diagnosed by physical exam alone. Breast ultrasound may also be used to help doctors guide a biopsy needle into some breast lesions. (ACS, 2016)
Computer-Aided Detection (CAD) for Ultrasound: CAD systems for ultrasound use pattern recognition methods to help radiologists analyze images and automate the reporting process. These systems have been developed to promote standardized breast ultrasound reporting. (ACS, 2016)

Computer-Aided Detection (CAD) with MRI of the Breast: Computer-aided detection has been used to aid radiologists’ interpretation of contrast-enhanced MRI of the breast, which is sometimes used as an alternative to mammography or other screening and diagnostic tests because of its high sensitivity in detecting breast lesions, even among those in whom mammography is less accurate (e.g., younger women and those with denser breasts). (ACS, 2016)

Computer-Aided Tactile Breast Imaging: Tactile breast imaging includes placing a tactile array sensor in contact with the breast. As the clinician gently moves the hand-held sensor across the breast and underarm area, data signals are then processed into multi-dimensional color images that instantly appear on a computer screen in real-time, allowing the clinician to view the size, shape, hardness and location of suspicious masses immediately. (ACS, 2016)

Electrical Impedance Scanning (EIS): EIS was developed as a confirmatory test to be used in conjunction with mammography. The device detects abnormal breast tissue using small electrical currents. Since malignant tissue tends to conduct more electricity than normal tissue, the electrical current produced creates a conductivity map of the breast which automatically identifies sites that appear suspicious. The transmission of electricity into the body is via an electrical patch on the arm or a handheld device which travels to the breast. This is measured by a probe on the surface of the skin. (ACS, 2016)

Magnetic Resonance Elastography (MRE) of the Breast: MRE of the breast is a phase-contrast-based MRI technique that is based upon quantitative differences in the mechanical properties of normal and malignant tissues. Specifically, the elastic modulus of breast cancer tissue is approximately 5- to 20-fold higher than that of the surrounding fibroglandular tissue, i.e., breast cancers are usually harder than normal tissues. This difference can be measured by applying a known stressor and measuring the resulting deformation. MRE is performed by a radiologist in an MRI suite equipped with the electromechanical driver and integrated radiofrequency coil unit. (ACS, 2016)

Magnetic Resonance Imaging (MRI): MRI is a non-invasive imaging modality that uses magnetic and radiofrequency fields to image body tissue producing very detailed, cross-sectional pictures of the body. Inconsistent with CT, MRI uses no ionizing radiation and is generally a safe procedure. MRI is sometimes used in combination with mammography. (National Institute of Biomedical Imaging, 2017)

Molecular Breast Imaging (MBI): Procedure that uses a radioactive tracer and special camera to find breast cancer. Rather than simply taking a picture of a breast, molecular breast imaging is a type of functional imaging. This means that the pictures it creates show differences in the activity of the tissue.

Positron Emission Mammography (PEM): PEM is a new imaging modality that has higher resolution than PET-CT and can be performed on patients unable to have an MRI scan. PEM performs high-resolution metabolic imaging for breast cancer using an FDG tracer. The PEM detectors are integrated into a conventional mammography system, allowing acquisition of the emission images immediately after the mammogram.

**Applicable Codes**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

Coding Clarification: Computer-aided detection (CAD) is included with the MRI breast CPT 77048 and 77049 procedures. If CAD is performed with these codes, there is no additional reimbursement.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0422T</td>
<td>Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral</td>
</tr>
<tr>
<td>CPT Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>76376</td>
<td>3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation</td>
</tr>
<tr>
<td>76377</td>
<td>3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with; image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation</td>
</tr>
<tr>
<td>76391</td>
<td>Magnetic resonance (e.g., vibration) elastography</td>
</tr>
<tr>
<td>76498</td>
<td>Unlisted magnetic resonance procedure (e.g., diagnostic, interventional)</td>
</tr>
<tr>
<td>76499</td>
<td>Unlisted diagnostic radiographic procedure</td>
</tr>
<tr>
<td>76641</td>
<td>Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete</td>
</tr>
<tr>
<td>76642</td>
<td>Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited</td>
</tr>
<tr>
<td>77046</td>
<td>Magnetic resonance imaging, breast, without contrast material; unilateral</td>
</tr>
<tr>
<td>77047</td>
<td>Magnetic resonance imaging, breast, without contrast material; bilateral</td>
</tr>
<tr>
<td>77048</td>
<td>Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral</td>
</tr>
<tr>
<td>77049</td>
<td>Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral</td>
</tr>
<tr>
<td>77065</td>
<td>Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral</td>
</tr>
<tr>
<td>77066</td>
<td>Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral</td>
</tr>
<tr>
<td>77067</td>
<td>Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed</td>
</tr>
</tbody>
</table>

HCPCS Code | Description |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>S8080</td>
<td>Scintimammography (radioimmunoscintigraphy of the breast), unilateral, including supply of radiopharmaceutical</td>
</tr>
</tbody>
</table>

CPT® is a registered trademark of the American Medical Association

Description of Services

Regular screening is the most reliable method for detecting breast cancer early when treatment is the most effective. Screening recommendations vary according to breast cancer risk, and several tools are available to approximate breast cancer risk based on various combinations of risk factors. Current methods of breast screening and diagnosis include breast self-examination, clinical breast exam, ultrasonography, mammography, and magnetic resonance imaging.

Mammography remains the generally accepted standard for breast cancer screening and diagnosis. However, efforts to provide new insights regarding the origins of breast disease and to find different approaches for addressing several key challenges in breast cancer, including detecting disease in mammographically dense tissue, distinguishing between malignant and benign lesions, and understanding the impact of neoadjuvant chemotherapies, has led to the investigation of several novel methods of breast imaging for breast cancer management.
Clinical Evidence

Automated Breast Ultrasound System (ABUS)

An archived 2013 Hayes report evaluating automated breast ultrasound system (ABUS), found that the results presented in most of the study abstracts report overall favorable results when using three-dimensional automated breast ultrasound. Further review is required to confirm abstract content and, therefore, conclusions about the safety and effectiveness of this technology cannot be made until a full assessment has been completed.

Hellgren et al. (2017) conducted a study to compare the sensitivity and specificity of Automated Breast Volume Scanners (ABVS) to handheld breast US for detection of breast cancer in the situation of recall after mammography screening. A total of 113 women, five with bilateral suspicious findings, undergoing handheld breast US due to a suspicious mammographic finding in screening, underwent additional ABVS. The methods were assessed for each breast and each detected lesion separately and classified into two categories: breasts with mammographic suspicion of malignancy and breasts with a negative mammogram. Results Twenty-six cancers were found in 25 women. In the category of breasts with a suspicious mammographic finding, the sensitivity of both handheld US and ABVS was 88% (22/25). The specificity of handheld US was 93.5% (87/93) and ABVS was 89.2% (83/93). In the category of breasts with a negative mammography, the sensitivity of handheld US and ABVS was 100% (1/1). The specificity of handheld US was 100% (102/102) and ABVS was 94.1% (96/102). The authors concluded that ABVS can potentially replace handheld US in the investigation of women recalled from mammography screening due to a suspicious finding. Due to the small size of this study population, further investigation with larger study populations is necessary before the implementation of such practice.

Kim et al (2016) conducted a prospective study to compare the diagnostic performance of handheld ultrasound (US) and an automated breast volume scanner (ABVS) as second-look US techniques subsequent to preoperative breast magnetic resonance imaging (MRI). From March to September 2014, both types of second-look US examinations were performed on 40 patients with breast cancer who had 76 additional suspicious lesions detected via preoperative breast MRI. Each second-look US modality was reviewed independently and the detection rate of each, the correlation between the detection rate, and the MRI factors (size, distance, and enhancement type) were evaluated. The detection rate of the ABVS was higher than that of handheld US for the second-look examination (94.7% versus 86.8%). Among the 76 total lesions, 7 were only identified by the ABVS, 1 was only found by handheld US, and 3 were not detected by either the ABVS or handheld US. When we analyzed the correlation between the detection rate and MRI factors, the only meaningful factor was the enhancement type. The ability to detect a non-mass lesion was lower than the ability to detect a mass-type lesion for both the ABVS and handheld US. It was concluded that for a second-look US examination subsequent to preoperative breast MRI in patients with breast cancer, the ABVS is a more efficient modality than handheld US for preoperative evaluations. However, both techniques have limitations in detecting non mass lesions. This study is limited to a small sample size.

Prosch et al. (2011) conducted a prospective diagnostic study. The study examined 148 breasts of 76 patients with handheld ultrasound (US) and ABUS. The ABUS data were evaluated separately by two investigators. The inter-observer agreement for the breast imaging reporting and data system (BI-RADS) classification among the two observers using ABUS was high, the agreement with handheld US was moderate. The sensitivity in the detection of breast cancer was 87.5% for handheld US and 75% for the ABUS evaluation by observer 1. The sensitivity was 87.5% for the ABUS evaluation and 83% for mammography by observer 2. The authors concluded that ABUS examinations focusing on the BIRADS classification have low inter-observer variability, compared to handheld US.

Magnetic Resonance Imaging of the Breast

Professional Societies/Guidelines

American Cancer Society (ACS, 2017)

The ACS guidelines specifically recommended against annual MRI screening in women at less than a 15% lifetime risk of breast cancer. The available data for MRI imaging is inconclusive for its use for routine screening in women who are not at high risk.

American College of Obstetricians and Gynecologists (ACOG, 2019)

The ACOG recommends routine screening with use of digital mammography for women diagnosed with dense breasts. They do not recommend routine use of alternative or adjunctive tests to screening mammography in women with dense breasts who are asymptomatic and have no additional risk factors. The College strongly supports additional research to identify more
effective screening methods that will enhance meaningful improvements in cancer outcomes for women with dense breasts and minimize false-positive screening results. ACOG also recommends that health care providers comply with state laws that may require disclosure to women of their breast density as recorded in a mammogram report.

**American College of Radiology Appropriateness Criteria for Breast Cancer Screening (2017)**

The American College of Radiology Appropriateness Criteria for Breast Cancer Screening considers MRI for screening high-risk women including women with a BRCA gene mutation and their untested first-degree relatives, women with a history of chest irradiation between 10 to 30 years of age, and women with 20% or greater lifetime risk of breast cancer usually appropriate.

**American Society of Breast Surgeons (ASBrS, 2017)**

A consensus guideline by the American Society of Breast Surgeons on diagnostic and screening magnetic resonance imaging of the breast also supports the use of MRI as a screening technique in women. The guideline particularly supports women age 25 or older with a BRCA gene mutation, women with other germline mutations known to predispose to a high risk of breast cancer, women with a history of chest irradiation, and women with a 20%-25% or greater estimated lifetime risk of breast cancer based on models primarily based on family history.

**Computer-Aided Detection with MRI of the Breast**

The NCCN guidelines for Breast Cancer Screening and Diagnosis (2018) does not address the use of computer aided detection (CAD)/computer aided evaluation (CAE) for breast MRI testing.

The BCBSA TEC completed a technology assessment in 2006 for CAD with MRI and concluded that there is insufficient evidence to assess whether the use of CAD systems would maintain or increase the sensitivity, specificity, and recall rates of MRI of the breast. Given the inability to evaluate these intermediate outcomes, it is not possible to assess the impact of CAD on health outcomes such as treatment success among breast cancer patients or survival (BCBSA, 2006c).

**Professional Societies**

**American College of Radiology (ACR, 2014)**

The ACR Practice Guideline for the performance of screening and diagnostic mammography states “Double reading and computer-aided detection (CAD) may slightly increase the sensitivity of mammographic interpretation and may be used. However, this sensitivity is at the expense of decreased specificity with increased recall and biopsy rates.”
**Computer-Aided Tactile Breast Imaging**

The current evidence consists of very low-quality, uncontrolled studies of the diagnostic efficacy for either tactile breast imaging device. The impact of these devices on patient outcomes has not been determined.

There is significant potential for bias in these studies that could result in hyper-inflated estimates of diagnostic accuracy of tactile breast imaging relative to other screening modalities. Limitations to the research include insufficient reporting of the referral process and work-up prior to tactile breast imaging, lack of randomization, unclear blinding, and inconsistent application of the gold standard.

Tasoulis et al. (2014) unnecessary referrals of patients with breast lumps represent a significant issue, since only a few patients actually have lumps when examined by a breast specialist. Tactile imaging (TI) is a novel modality in breast diagnostics armamentarium. The aim of this study was to assess TI's diagnostic performance and compare it to clinical breast examination (CBE). This is a prospective, blinded, comparative study of 276 consecutive patients. All patients underwent conventional imaging and tissue sampling if either a radiological or a palpable abnormality was present. Sensitivity, specificity and positive and negative predictive values for CBE and TI were calculated. Radiological findings and final diagnosis based on histology and/or cytology were used as reference standards. Receiver operator characteristic (ROC) curve analysis was also performed for each method. Sensitivity and specificity of TI in detecting radiologically proven abnormalities were 85.5% and 35%, respectively. CBE's sensitivity was 80.3% and specificity 76%. In detecting a histopathological entity according to histology/cytology, sensitivity was 88.2% for TI and 81.6% for CBE. Specificity was 38.5% and 85.7% for TI and CBE, respectively. These results suggest a trend towards higher sensitivity of TI compared to CBE but significantly lower specificity. Subgroup analysis revealed superior sensitivity of TI in detecting a histological entity in pre-menopausal women. However, CBE's overall performance was superior compared to TI's according to ROC curve analysis. Although further research is necessary, the use of TI by the primary care physician as a selection tool for referring patients to a breast specialist should be considered especially in pre-menopausal women.

**Electrical Impedance Scanning (EIS)**

There is a lack of evidence in the published literature to show that electrical impedance scanning for the detection and classification of breast lesions can predict clinical events, alter treatment or is effective as or more effective than currently used methods.

The 2018 NCCN Clinical Practice Guideline for Breast Cancer Screening and Diagnosis does not mention EIS as a diagnostic tool in the diagnosis or management of breast tumors.

An archived 2011 Hayes technology brief evaluating electrical impedance scanning (EIS), found that EIS can detect malignant breast tissue in some patients; however, the sensitivity, specificity, and negative predictive value (NPV) of this technique do not appear sufficient to rely on it as a substitute in patients who have suspicious lesions. Further studies of EIS are needed to assess its effectiveness as an adjunct to mammography, in women who meet all criteria specified by the FDA for use of EIS.

In a prospective, multi-center study, Wang et al (2010) reported the sensitivity and specificity for the combination of EIS and ultrasound in identifying breast cancer and calculated the relative risk of breast cancer in young women. The young women (583 cases) scheduled for mammary biopsy underwent EIS and ultrasound, respectively. EIS and ultrasound results were compared with final histopathology results. Of the 583 cases, 143 were diagnosed with breast cancer. The relative probability of breast cancer for the young women was detected by EIS, ultrasound, and the combination method. The authors concluded that the combination of EIS and ultrasound is likely to become an applicable method for early detection of breast cancer in young women.

A prospective, multicenter clinical trial by Stojadinovic et al. (2005) evaluated EIS in 1,103 women. Twenty-nine cancers with a mean tumor size 1.7 cm were confirmed thru biopsy. Electrical impedance scanning had 17% sensitivity, 90% specificity, and a negative predictive value (NPV) of 98%. Statistically significant increases in specificity were observed for women who were premenopausal and women who were not using hormone replacement therapy. False-positive rates were increased in postmenopausal women and those taking exogenous hormones. While the authors concluded that EIS appears promising for early detection of breast cancer, the increased false positive rates in postmenopausal women and those taking exogenous hormones is concerning.
In 2006, Stojadinovic et al. conducted a follow-up study. The results were reported for 1,361 consecutively enrolled asymptomatic women ages 30–39 years (used to measure specificity), and 189 women ages 30–45 years who had a suspicious breast abnormality and were referred for biopsy (used to measure sensitivity). The researchers assumed that none of the women in the first group had breast cancer and, consequently, that any positive EIS results were false positives; no follow-up data were collected on these women. In the second group of women with breast abnormalities, 59.3% were aged 40–45. The specificity in the first group was 95% (assuming all positive results were incorrect); the specificity in the second group among women with benign breast disease was 80.7%. The sensitivity in the second group was 38%, but it ranged from 29% among women aged 30–39 to 42% among women aged 40–45. The authors concluded that the relative probability that a woman with a positive EIS result currently has breast cancer is 7.68 and that about one cancer would be detected for every 77 women referred for follow-up. This study has a number of limitations, including the assumption that none of the women in the specificity arm had cancer (the authors argue that this assumption is likely to have little impact on the overall results given the low prevalence of cancer in this population); the age difference between the two groups (and the difference in sensitivity by age, although whether or not this is statistically significant is not reported), and the measurement of sensitivity and specificity in two different populations. The authors themselves conclude that the results are encouraging but that “further large-scale, long-term follow-up studies are required and underway in the intended use populations.

Magnetic Resonance Elastography of the Breast

Researchers have tested the feasibility of breast elastography and the results confirm the hypothesis that breast elastography can quantitatively depict the elastic properties of breast tissues and reveal high shear elasticity in known breast tumors. However, the clinical benefits of elastography imaging are still under evaluation and no clinical diagnosis can be made other than being able to tell whether or not a structure inside the patient is stiffer than another one. Further research is needed to evaluate the potential clinical applications of breast elastography, such as detecting breast carcinoma and characterizing suspicious breast lesions.

A prospective study by Siegmann et al. (2010) evaluated the value of adding magnetic resonance elastography (MRE) to contrast-enhanced MR imaging (MRI) for evaluating breast lesions in 57 patients. The sensitivity of MRI was 97.3% whereas specificity was 55%. If contrast-enhanced MRI was combined with $\alpha_0$ (indicator of tissue stiffness), the diagnostic accuracy could be significantly increased. The authors concluded that combining MRE with MRI increase the diagnostic performance of breast MRI; however, larger studies are needed to validate the results and to identify the patients best suited for a combined procedure.

Molecular Imaging

The published literature on molecular breast imaging is limited by a number of factors. The studies include populations that usually do not represent those encountered in clinical practice and that have mixed indications. There are methodologic limitations in the available studies, which have been judged to have medium to high risk of bias, and they lack information on the impact on therapeutic efficacy. Limited evidence on the diagnostic accuracy of molecular imaging reports that these tests have a relatively high sensitivity and specificity for detecting malignancy. However, the evidence does not establish that this imaging improves outcomes when used as an adjunct to mammography for breast cancer screening. Larger, higher-quality studies are required to determine whether molecular imaging has a useful role as an adjunct to mammography.

Guo et al (2016). In a 2016 systematic review and meta-analysis, the authors sought to establish if Tc-99m sestamibi scintimammography had acceptable sensitivity in the prediction of neoadjuvant chemotherapy responses in breast cancer. Electronic database searches were carried out for relevant publications in English, and fourteen studies, for a total of 503 individuals, fulfilled the inclusion criteria. The results indicated that Tc-99m MIBI scintimammography had acceptable sensitivity in the prediction of neoadjuvant chemotherapy response in breast cancer; however, its relatively low specificity showed that a combination of other imaging modalities would still be needed. Subgroup analysis indicated that performing early mid-treatment Tc-99m MIBI scintimammography (using the reduction rate of one or two cycles or within the first half-courses of chemotherapy compared with the baseline) was better than carrying out later (after three or more courses) or post-treatment scintimammography in the prediction of neoadjuvant chemotherapy response.

Brem at al (2016). The authors conducted this retrospective review to determine the incremental increase in breast cancer detection when BSGI is used as an adjunct to mammography in women at increased risk for breast cancer. 849 patients undergoing BSGI from April 2010 through January 2014 were retrospectively reviewed. Eligible patients were identified as women at increased risk for breast cancer and whose most recent mammogram was benign. Examinations exhibiting focally
increased radiotracer uptake were considered positive. Incremental increase in cancer detection was calculated as the percentage of mammographically occult BSGI-detected breast cancer and the number of mammographically occult breast cancers detected per 1,000 women screened. Reviewed for this study were patients in whom 14 BSGI examinations detected mammographically occult breast cancer. Patients ranged in age from 26 to 83 with a mean age of 57. Eleven of 14 cancers were detected in women with dense breasts. The addition of BSGI to the annual breast screen of asymptomatic women at increased risk for breast cancer yields 16.5 cancers per 1,000 women screened. When high-risk lesions and cancers were combined, BSGI detected 33.0 high-risk lesions and cancers per 1,000 women screened. The authors concluded that BSGI is a reliable adjunct modality to screening mammography that increases breast cancer detection by 1.7% (14/849) in women at increased risk for breast cancer, comparable to results reported for breast MRI. BSGI is beneficial in breast cancer detection in women at increased risk, particularly in those with dense breasts. Limitation of this study is retrospective study design.

In the 2013 ECRI Evidence Report, Noninvasive Diagnostic Tests for Breast Abnormalities found that only women with a pre-scintimammography suspicion of malignancy of 5 percent or less will have their post-scintimammography suspicion of malignancy change sufficiently to suggest that a change in patient management may be appropriate.

A 2013 TEC Assessment by the Blue Cross Blue Shield Association evaluated the use of BSGI, or scintimammography with breast-specific gamma camera as a diagnostic modality for screening to detect breast tumors and concluded that there is no evidence of improved health outcomes.

An Archived 2015 Hayes report evaluating breast-specific gamma imaging (BSGI) found that the available evidence does not provide conclusive evidence that breast-specific gamma imaging can be relied on rather than biopsy, US, or MRI in women who have suspicious breast lesions on mammograms. In several of the reviewed studies, BSGI detected some cancerous lesions that were not detected by mammography; however, these studies did not report whether the increased detection corresponded to a statistically significant increase in the sensitivity of BSGI compared with mammography. In the studies that provided data on patient management, BSGI was not rigorously compared with MRI or US to determine whether it was more effective. Only two studies reported the statistical significance of results, both of which indicated that BSGI was more specific than MRI. Although further studies may indicate that breast-specific gamma imaging has greater sensitivity than ultrasonography and MRI, breast-specific gamma imaging has the disadvantage that it exposes the patient to radiation. In addition, unlike biopsy, breast-specific gamma imaging does not provide a definitive diagnosis since it incorrectly indicates that 15% to 40% of benign lesions are cancerous. The quality of the evidence is low due to the predominately retrospective study design, small sample sizes, and, in some cases, lack of statistical analysis of results. Additional studies are needed to determine the place in therapy of BSGI versus the alternatives.

Kim (2012) evaluated the adjunctive benefits of BSGI versus MRI in breast cancer patients with dense breasts. This study included a total of 66 patients with dense breasts (breast density greater than 50%) and already biopsy-confirmed breast cancer. All of the patients underwent BSGI and MRI as part of an adjunct modality before the initial therapy. Of 66 patients, the 97 undetermined breast lesions were newly detected and correlated with the biopsy results. Twenty-six of the 97 breast lesions proved to be malignant tumors; the remaining 71 lesions were diagnosed as benign tumors. The sensitivity and specificity of BSGI were 88.8% and 90.1% respectively, while the sensitivity and specificity of MRI were 92.3% and 39.4%, respectively. MRI detected 43 false-positive breast lesions, 37 (86.0%) of which were correctly diagnosed as benign lesions using BSGI. In 12 malignant lesions less than 1 cm, the sensitivities of BSGI and MR imaging were 83.3% and 91.7% respectively. The author concluded that BSGI showed an equivocal sensitivity and a high specificity compared to MRI in the diagnosis of breast lesions. In addition, BSGI had a good sensitivity in discriminating breast cancers less than or equal to 1 cm. The results of this study suggested that BSGI could play a crucial role as an adjunctive imaging modality which can be used to evaluate breast cancer patients with dense breasts. The study was limited by small sample size; larger prospective studies are needed to determine the true sensitivity and specificity of BSGI.

Based on 44 studies of scintimammography, an analysis found that for non-palpable lesions, the specificity of scintimammography was 39.2% (at a fixed 95% sensitivity). At the mean threshold of the included studies, the sensitivity was 68.7% and specificity was 84.8%. The analysis also found that in women with non-palpable lesions, the negative likelihood ratio of scintimammography was 0.41 (i.e., if a woman with a non-palpable lesion is diagnosed as having no cancer by scintimammography, her chance of having breast cancer drops from 20% to 9.3%). (AHRQ, 2006, updated 2012)

A meta-analysis of scintimammography included 5,473 patients from studies performed since 1997. The overall sensitivity was 85% and the specificity was 84% for single-site trial studies, and for multi-center trial studies the overall sensitivity was 85% and
the specificity was 83%. (Hussain and Buscombe, 2006) Another meta-analysis evaluating scintimammography included 5,340 patients from studies published between January 1967 and December 1999. The aggregated summary estimates of sensitivity and specificity for scintimammography were 85.2% and 86.6% respectively. The authors concluded that scintimammography may be used effectively as an adjunct to mammography when additional information is required to reach a definitive diagnosis. The authors also indicated that the role of scintimammography should be assessed on the basis of large, multi-center studies. (Liberman et al., 2003)

**Professional Societies**

**American Cancer Society (ACS, 2016)**

According to ACS guidelines, routine breast cancer screening with scintimammography is not recommended.

In a 2016 update on experimental breast imaging, the ACS states that while this test is approved by the Food and Drug Administration (FDA) to help classify tumors found on mammograms, at this time there hasn’t been enough clinical testing to use it in breast cancer screening.

**American College of Radiology (ACR, 2017)**

According to appropriateness criteria for breast cancer screening, there is insufficient evidence to support the use of breast specific gamma imaging (BSGI). Also, the relatively high radiation dose currently associated with BSGI/MBI has prompted the American College of Radiology to recommend against the use for screening.

**Society of Breast Imaging (SBI, 2013)**

In the SBI Position Statement entitled ‘Use of Alternative Imaging Approaches to Detection of Breast Cancer’ states that the following: “Often predicated on the increased vascularity associated with cancer, techniques to detect increased heat production, oxygen consumption, electrical impedance, light absorption, microwave transmission, and nitrous oxide production have indicated changes in the breast containing cancer that may assist in detection or diagnosis. While many of these approaches have received FDA approval for safety, such techniques remain either experimental or investigational, given the lack of standard techniques that can be uniformly applied and paucity of sufficient research to substantiate reliability of results. None of these tests have been shown to reduce mortality among tested women in randomized controlled trials.” Mammography provides the only examination satisfying both the benchmarks for screening and diagnosis based on objective and randomized clinical trials.

**Society of Nuclear Medicine and Molecular Imaging (SNMMI, 2012) (formerly Society of Nuclear Medicine)**

SNM published updated 2012 procedure standards for breast scintigraphy with breast-specific gamma cameras that indicate that further study is needed to determine the population and usefulness most likely to benefit from this procedure. This guideline lists potential indications and cites references for each indication but does not provide a systemic review of the literature, including assessment of study quality. The guideline is based on consensus, and most of it is devoted to procedures and specifications of the examination, documentation and recording, quality control and radiation safety.

**U.S. Food and Drug Administration (FDA)**

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Mammographic x-ray systems are classified as Class II devices. The FDA regulates the marketing of mammography devices and regulates the use of such devices via the Mammography Quality Standards Act (MQSA). The FDA has granted pre-market approval to several digital mammography systems (product code MUE) for breast cancer screening and diagnosis.

**Magnetic Resonance Elastography of the Breast**

Refer to the following website for more information on devices used for elastography of the breast (search by product name LNH in device name section): [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm).
Breast Specific Gamma Imaging (BSGI)
BSGI for diagnosing breast cancer is a procedure and, therefore, is not subject to FDA regulation. However, the equipment used to conduct BSGI is subject to FDA regulation. The cameras used during BSGI are considered Class I radiologic devices. A scintillation (gamma) camera is a device intended to image the distribution of radionuclides in the body by means of a photon radiation detector. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm.

Automated Breast Ultrasound System (ABUS)
Automated breast (or whole breast) ultrasound devices are regulated by the FDA as Class III devices. Refer to the following website for more information on devices used for Automated Breast Ultrasound Systems (search by product name in device name section): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm.

Electrical Impedance Scanning
These devices are approved as an adjunct to mammography in patients whose lesions are American College of Radiology (ACR) Breast Imaging-Reporting and Data System (BI-RADS) category III (probably benign) or IV (suspicious abnormality), based on mammography. Refer to the following website for more information on devices used for Electrical Impedance Scanning (search by product name in device name section): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm.

Computer-Aided Detection for MRI of the Breast
Refer to the following website for more information on devices used for Computer-Aided Detection for MRI of the Breast (search by product name in device name section): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm.

Computer-Aided Detection for Ultrasound
Refer to the following website for more information on devices used for Computer-Aided Detection for Ultrasound (search by product names MYN and LLZ in device name section): http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. (Accessed June 3, 2020)

Centers for Medicare and Medicaid Services (CMS)
Medicare covers screening and diagnostic mammography when criteria are met; see the National Coverage Determination (NCDs) for Mammograms (220.4) and Ultrasound Diagnostic Procedures (220.5). Medicare does not have NCDs that specifically address the following procedures:
- Automated Breast Ultrasound System (ABUS)
- Breast Magnetic Resonance Imaging (MRI)
- Breast Specific Gamma Imaging (BSGI) (also known as scintimammography)
- Breast Ultrasound
- Computer Aided Detection (CAD) for MRI of the Breast
- Computer Aided Detection (CAD) for Ultrasound
- Computer Aided Tactile Breast Imaging
- Digital Mammography
- Electrical Impedance Scanning (EIS)
- Magnetic Resonance Elastography (MRE) of the Breast

Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist; see the following LCDs/LCAs: Breast Imaging: Breast Echography (Sonography)/Breast MRI/Ductography, Breast Imaging Mammography/Breast Echography (Sonography)/Breast MRI/Ductography, 3D Interpretation and Reporting of Imaging Studies, Tomosynthesis-Guided Breast Biopsy, Noncovered Services and Category III CPT Codes. (Accessed June 4, 2020)
References


Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Breast-specific gamma imaging (BSGI), molecular breast imaging (MBI), or scintimammography with breast-specific gamma camera. TEC Assessments 2013; Volume 28.


---

**Policy History/Revision Information**

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/20120</td>
<td>Updated notation to clarify this policy does not address the preventive benefit for breast cancer screening (including mammography)</td>
</tr>
<tr>
<td></td>
<td>Revised language pertaining to breast magnetic resonance imaging (MRI) to indicate breast MRI is proven and medically necessary for individuals who are at high risk for breast cancer as defined as having any of the following:</td>
</tr>
<tr>
<td></td>
<td>History of radiation to the chest between ages 10 and 30</td>
</tr>
<tr>
<td></td>
<td>Lifetime risk estimated at greater than or equal to 20% based on models that are largely defined by family history (e.g., Gail, Claus, Tyrer-Cuzick or BRCAPRO)</td>
</tr>
<tr>
<td></td>
<td>Personal history of breast cancer (not treated with bilateral mastectomy)</td>
</tr>
<tr>
<td></td>
<td>Personal history with any of the following:</td>
</tr>
<tr>
<td></td>
<td>Li-Fraumeni Syndrome (TP53 mutation); or</td>
</tr>
<tr>
<td></td>
<td>Confirmed BRCA 1 or BRCA 2 gene mutations; or</td>
</tr>
<tr>
<td></td>
<td>Peutz-Jehgers Syndrome (STK11, LKB1 gene variations); or</td>
</tr>
<tr>
<td></td>
<td>PTEN gene mutation</td>
</tr>
<tr>
<td></td>
<td>Family history with any of the following:</td>
</tr>
<tr>
<td></td>
<td>At least one first-degree relative who has a BRCA1 or BRCA2 mutation; or</td>
</tr>
<tr>
<td></td>
<td>First-degree relative who carries a genetic mutation in the TP53 or PTEN genes (Li-Fraumeni syndrome and Cowden and Bannayan-Riley-Ruvalcaba syndromes, or Peutz-Jehgers Syndrome); or</td>
</tr>
<tr>
<td>Date</td>
<td>Summary of Changes</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------</td>
</tr>
<tr>
<td></td>
<td>▪ At least two first-degree relatives with breast or ovarian cancer; or</td>
</tr>
<tr>
<td></td>
<td>▪ One first-degree relative with bilateral breast cancer, or both breast and ovarian cancer; or</td>
</tr>
<tr>
<td></td>
<td>▪ First or second-degree male relative (father, brother, uncle, grandfather) diagnosed with breast cancer</td>
</tr>
<tr>
<td></td>
<td>● Replaced language indicating “scintimammography is unproven and not medically necessary” with “Molecular Breast Imaging (e.g., scintimammography, positron emission mammography) is unproven and not medically necessary”</td>
</tr>
<tr>
<td></td>
<td>Definitions</td>
</tr>
<tr>
<td></td>
<td>● Added definition of:</td>
</tr>
<tr>
<td></td>
<td>o Molecular Breast Imaging (MBI)</td>
</tr>
<tr>
<td></td>
<td>o Positron Emission Mammography (PEM)</td>
</tr>
<tr>
<td></td>
<td>Supporting Information</td>
</tr>
<tr>
<td></td>
<td>● Updated Description of Services, Clinical Evidence, CMS, and References sections to reflect the most current information</td>
</tr>
<tr>
<td></td>
<td>● Archived previous policy version 2019T0375Y</td>
</tr>
</tbody>
</table>

**Instructions for Use**

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.